ONCS Stock UPDATES Oncosec Medical Inc (ONCS) 0.5300 09/11/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2014 at 12:45 AM

Oncosec Medical Inc (ONCS) 0.5300 $ONCS

OncoSec Medical to Present Data at ESMO 2014 Congress
Business Wire - Tue Sep 09, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and pre-clinical studies at the European Society for Medical Oncology (ESMO) 2014 Congress, to be held September 26-30 in Madrid, Spain. OncoSec is proud to be presenting an abstract titled, "Immune correlates of intratumoral IL-12 electroporation", as part of a poster presentation taking place 12:45 PM - 1:45 PM CEST on Sunday, September 28th.

OTC Daily News Report
PR Newswire Europe - Wed Sep 03, 8:05AM CDT
LONDON, September 3, 2014 /PRNewswire/ --

OncoSec Medical to Present at Five Events in September
Business Wire - Tue Sep 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at five events in September. The company's agenda includes a number of high-profile scientific and investment conferences.

OTC Daily Stock News: Apptigo International, Inc. Onco Sec Medical Inc., Monitise PLC, American Green, Inc. Terra Tech Corp, MusclePharm Corp
PR Newswire Europe - Thu Aug 07, 7:02AM CDT
LONDON, August 7, 2014 /PRNewswire/ --

OncoSec Medical names Dr Holbrook Kohrt to SAB
M2 - Wed Aug 06, 6:19AM CDT
Biopharmaceutical company OncoSec Medical (OTCQB:ONCS) disclosed on Wednesday that Dr Holbrook Kohrt, MD, PhD has been elected to its Scientific Advisory Board.

OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board
Business Wire - Wed Aug 06, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline.

OncoSec Medical To Present at 2014 DNA Vaccine Conference
Business Wire - Thu Jul 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that several company representatives will present at the International Society of DNA Vaccines (ISDV) 2014 DNA Vaccine Conference, being held July 21-23, 2014 at the Westin San Diego Gaslamp Quarter Hotel in San Diego, CA.

OncoSec Medical To Present at Bioelectrochemistry Gordon Research Conference on July 8 and July 10
Business Wire - Wed Jul 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that Robert Pierce, M.D., Chief Medical Officer, and Richard Heller, Ph.D., Scientific Advisory Board member, will present at the Bioelectrochemistry Gordon Research Conference being held July 6-11, 2014 at the University of New England in Biddeford, ME.

OncoSec Medical Appoints Dr. Soldano Ferrone to Scientific Advisory Board
Business Wire - Wed Jun 25, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.

OncoSec Medical Announces YTD Results as of April 30, 2014
Business Wire - Fri Jun 13, 8:00AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced financial results for the nine months ended April 30, 2014.

OncoSec Medical Issues Annual Letter To Shareholders
Business Wire - Thu Jun 12, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, today issued the following letter from Punit Dhillon, President and CEO, to the company's shareholders:

OncoSec Medical to Present at Two Conferences in New York City in April
Business Wire - Mon Mar 31, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April.

PUNIT DHILLON of OncoSec Medical Incorporated (ONCS)-Other O bought Shares of ONCS
M2 - Fri Mar 21, 7:39AM CDT
Reported by InsiderCow.com at 2014-03-20 14:21:26 ET

OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Mon Mar 17, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).

OncoSec Medical to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial
Business Wire - Wed Mar 12, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.

OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).

OTC Daily Alert Stock Watch - OncoSec Medical Incorporated (OTCQB: ONCS)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

OncoSec Medical to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York, New York on Monday, February 10 at 4:00 p.m. (EST) in the third floor Basildon Suite.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viatris Declares Quarterly Dividend Amid Acquisition Buzz

A Dividend Declaration with a Side of Mergers Viatris, the healthcare giant operating on a global scale, has been making some noise recently. On the surface, it's another quarterly dividend—$0.12 per share, set to hit the pockets of shareholders on December 16. But there's a lot more cooking under the hood of this announcement that ticks just about every box for a...

Lululemon Faces Lawsuit Over Alleged Fraudulent Reporting

What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...

Greenberg Traurig's Stars Shine in Delaware's Legal Scene

Five Lawyers, One Prestigious List Eating lunch today, I nearly dropped my sandwich when I read that five top-notch attorneys from Greenberg Traurig have snagged spots on Delaware Today's 2026 Top Lawyers List. This isn't your everyday pat on the back; it's Delaware, the heavyweight champ of corporate law, after all. The Legal Eagles of Greenberg Traurig Kicking off this...

Samsung Ups Stake in TCL CSOT: A Game-Changer?

Samsung Electronics' Strategic Play Sometimes it takes a gutsy move to shake up the industry, and Samsung Electronics just went for it. Snagging a 10.16% stake in TCL CSOT isn't just some run-of-the-mill acquisition. It's a calculated chess piece placement in the cutthroat display tech arena. Unpacking the Stake Game This latest move shifts Samsung Display's stake to...

Black Friday Doubt Grows: Just 54% Trust Real Deals

Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...

LULU Under Fire: Class Action Opportunities Await

Lululemon Faces a Legal Storm If you're holding shares in Lululemon (NASDAQ: LULU), you might want to sit up and pay attention. Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, is gathering folks for a securities fraud class action lawsuit against Lululemon. They're pointing fingers at the company for cooking the books – or at least not being...

Askey & Icom Team Up: Trading Airwaves for Partnerships

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

Sectra Powers Radiology at Mount Sinai with AI Integration

AI and Radiology: A Match Made for Mount Sinai Today, we're diving into a technological leap that promises to shake up the healthcare sector—Sectra's integration of artificial intelligence with radiology at Mount Sinai Health System. The deal pairs Sectra's prowess in medical imaging IT and cybersecurity with the healthcare giant in New York, aiming to redefine how...

DarioHealth Taps Palumbo to Drive Healthcare Evolution

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Atlas-SSI Expands Grip in Water Control Space

Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...